Immunophenotypes of Burkitt�s lymphoma cell lines alter at different Epstein-Barr Virus (EBV) infection latency types

Abstract

Event Abstract Back to Event Immunophenotypes of Burkitt’s lymphoma cell lines alter at different Epstein-Barr Virus (EBV) infection latency types Irina Spaka1, 2*, Artjoms Spaks3, 4, Svetlana Kozireva2, Jevgenija Osmjana2, Madara Upmane2, 3, Rita Birkenfelde2, Vaira Kalnina2, Sandra Lejniece2, 5, 6 and Irina Kholodnyuk2 1 Riga Stradiņš University, Latvia 2 Riga Stradiņš University, August Kirchenstein Institute of Microbiology and Virology, Latvia 3 University of Latvia, Latvia 4 Pauls Stradins Clinical University Hospital, Thoracic Surgery Center, Latvia 5 Rīga Stradiņš University, Department of Internal diseases, Latvia 6 Riga Eastern University Hospital, Chemotherapeutic and Hematological Clinic, Latvia Epstein-Barr virus (EBV) is involved in the pathogenesis of endemic Burkitt’s lymphoma (BL). EBV-positive BL cell lines initially maintain the original tumor phenotype of EBV infection (latency I, LatI), but most of them drift toward a lymphoblast phenotype of EBV latency III (LatIII) during in vitro culturing. The aim of this study was to characterize the immunophenotypes of BL cell lines and to verify whether particular cell subsets association with the type of EBV infection. The phenotype analysis of two EBV-negative and eleven EBV-positive (three of LatI and eight of LatIII) BL cell lines was based on determination of CD19, CD10, CD38, CD27, and CD5 expression pattern by means of multicolor flow cytometry (pFC). The same approach was applied for the characterization of B-cell subpopulations in peripheral blood (PB) of 8 healthy adults. The EBV latency type was defined by RT-PCR using EBV transcript specific primers. In EBV-negative and LatI BL cell lines all cells displayed the CD19+CD10+CD38+ phenotype. In contrast, in three LatIII cell lines that were established by a single cell cloning, more than 90% of the cells were CD19+CD10−CD38+. Four original BL tumor-derived cell lines of LatIII consisted of two cell subsets, CD19+CD10+ and CD19+CD10−, in proportion of 28%-84% and 17%-72% of the cells, respectively. A fraction of the cells in these four LatIII BL cell lines displays the phenotype of PB circulating mature B cells (CD19+CD10−CD38+ CD27+ CD5−). This observation may suggest that expression of the EBV LatIII genes may promote the differentiation of malignant cells. Acknowledgements This work was supported by Swedish Cancer Foundation, Karolinska Institutet (Stockholm, Sweden), Latvian Council of Science, and by European Social Fund grant Nr. 2009/0221/1DP/1.1.1.2.0/09/APIA/VIAA/074 (Latvia). Keywords: Epstein-Barr virus (EBV), Burkitt’s lymphoma (BL), immunophenotype, Latency I (Lat I), Latency III (Lat III) Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Immune receptors and signaling Citation: Spaka I, Spaks A, Kozireva S, Osmjana J, Upmane M, Birkenfelde R, Kalnina V, Lejniece S and Kholodnyuk I (2013). Immunophenotypes of Burkitt’s lymphoma cell lines alter at different Epstein-Barr Virus (EBV) infection latency types. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00399 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 19 Mar 2013; Published Online: 22 Aug 2013. * Correspondence: Ms. Irina Spaka, Riga Stradiņš University, Riga, Latvia, irinapichura@yahoo.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Irina Spaka Artjoms Spaks Svetlana Kozireva Jevgenija Osmjana Madara Upmane Rita Birkenfelde Vaira Kalnina Sandra Lejniece Irina Kholodnyuk Google Irina Spaka Artjoms Spaks Svetlana Kozireva Jevgenija Osmjana Madara Upmane Rita Birkenfelde Vaira Kalnina Sandra Lejniece Irina Kholodnyuk Google Scholar Irina Spaka Artjoms Spaks Svetlana Kozireva Jevgenija Osmjana Madara Upmane Rita Birkenfelde Vaira Kalnina Sandra Lejniece Irina Kholodnyuk PubMed Irina Spaka Artjoms Spaks Svetlana Kozireva Jevgenija Osmjana Madara Upmane Rita Birkenfelde Vaira Kalnina Sandra Lejniece Irina Kholodnyuk Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.